Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRd-based Regimen Combined With BCMA CAR-T in Primary Plasma Cell Leukemia
NCT05979363Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2023
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-BCMA CAR-T in plasma cell leukemia (PCL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Safety and Tolerability up to 2 years and Minimal Residual Disease-negative rate. Started Aug 2023; status: recruiting.
02
Drugs
anti-BCMA CAR-T
03
Conditions
plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT05979363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05979363.